Strategic partnerships With a strong track record in cancer, neuroscience, immunology, and pediatric diseases and a focus on drug discovery collaborations, SBP presents ample opportunities for joint ventures, contract research, and licensing deals to accelerate therapeutic development.

Funding leverage SBP has a substantial funding footprint (revenue in the mid to high hundreds of millions) and a history of NIH grants, signaling openness to funded research programs and potential for service-based engagements or sponsored research collaborations.

Clinical and translational hub As an NCI-designated Cancer Center with a global partnerships network, SBP is well-positioned to pursue translational programs, clinical trial accelerations, and platform collaborations that require integrated biology, analytics, and regulatory navigation.

Talent and collaboration SBP emphasizes collaboration and education, with recent hires and expansion efforts; this suggests opportunities for professional training programs, sponsored symposia, external faculty collaborations, and technology licensing to support scientific workflows.

Tech-enabled discovery Utilizing a diverse tech stack across data processing, collaboration platforms, and software tooling indicates readiness for partnerships around bioinformatics, computational biology, and digital infrastructure to streamline discovery pipelines and scale drug discovery.